Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT04435600 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04435600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04435600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
July 14, 2020
Completion date
October 15, 2024
Enrollment
139 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis